Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Etoposide

50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.

DRUG

Cyclophosphamide

50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated

Trial Locations (7)

08816

Central Jersey Oncology Center, East Brunswick

08690

Robert Wood Johnson University Hospital/CINJ at Hamilton, Hamilton

07962

Morristown Memorial Hospital, Morristown

08901

Cancer Institute of New Jersey, New Brunswick

08903

Saint Peter's University Hospital, New Brunswick

07103

UMDNJ/Robert Wood Johnson Medical School, Newark

070901

Overlook Hospital, Summit

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER